Eisai lures Novartis exec to its US Oncology Unit

20 May 2019

The US subsidiary of Japanese drugmaker Eisai (TYO: 4523) has appointed Dr Luca Dezzani as vice president, US medical affairs, Oncology Business Group.

He will be responsible for creating the medical affair strategy for the company's oncology portfolio of both commercialized and investigational products in the USA. He will also oversee Eisai's Health Economics & Outcomes Research (HEOR), Medical Science Liaisons (MSL) and Medical Information & Education teams.

Welcoming Dr Dezzani to Eisai, Dr Kirk Shepard, senior VP, chief medical officer and head of global medical affairs for the Oncology Business Group, said: "He comes to Eisai at an extraordinary time, as we dedicate our efforts towards the investigation of multiple modalities that we hope will harness the potential of the human immune system to result in more immunology in oncology, and, ultimately, benefit more patients."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK